Boston Scientific slashes 2026 guidance third time. By Trisna Anggraini October 29, 2026 Boston Scientific reported a challenging third quarter, marked by a cyberattack and ongoing struggles in key product lines, prompting the company to slash its 2026 earnings and sales guidance for the third consecutive time. The medical device company now projects full-year revenue growth of 4.25%, down from a previous range of 5.5% to 6.5%. Adjusted earnings per share guidance was cut to $3.16 to $3.18 from $3.28 to $3.32, following an earlier February forecast of $3.43 to $3.49. The new guidance, released along with third-quarter results, is a far cry from what was projected at the beginning of the year, when Boston Scientific outlined 2026 sales growth expectations of 10.5% to 11.5%. The third-quarter results included a roughly $150 million revenue hit from a cyberattack that disrupted ordering, manufacturing, and shipping operations. This markedly lower impact compared with the $755 million in revenue losses attributed to a similar cyberattack during the year-ago period, showing the company's ongoing vulnerability to operational disruptions. Overall, Boston Scientific reported $5.14 billion in revenue, representing 1.5% growth compared to the prior year. CEO Mike Mahoney attributed the guidance reductions to persistent challenges in the Watchman and electrophysiology divisions, which historically drove significant growth. Watchman sales fell 6% year-over-year, while electrophysiology declined 5%, contrasting with 30% growth in Watchman sales and triple-digit gains in electrophysiology during 2025. Mahoney highlighted that the slowdown in the left atrial appendage closure market, which includes Watchman, stems from changes in patient identification and referral patterns, while electrophysiology's decline reflects competitive pressures in pulsed field ablation technology. The company also forecast a 3% to 1% sales decline in the fourth quarter and acknowledged that it will be challenged to grow sales and adjusted EPS next year. Boston Scientific's stock dropped nearly 7% to $42.02 following the announcement. The company also delayed its $14.5 billion acquisition of Penumbra, now expecting completion in early 2027 rather than 2026 due to the regulatory process taking a bit of time. "The regulatory process has taken a bit of time," Mahoney said. "We're still very confident in closing the transaction, but based on some of the discussions with the regulatory authorities, we anticipate the early first quarter close."

BSX stock crashes to 4-year lows: Boston Scientific sees Q4 sales declining, CEO remains confident in 'long-term strategy' Published: Oct 28 2026, 09:10 PM IST * FB * TW * Linkdin * Whatsapp * GNFollow Us For full year 2026, Boston Scientific expects reported sales growth of about 4.25%, down from its previous forecast of 5.5% to 6.5%. * The company lowered its full-year adjusted earnings outlook to $3.16 to $3.18 per share, down from $3.28 to $3.32 per share. * Q3 net sales rose 1.5% to $5.14 billion, exceeding Wall Street estimates of $5.04 billion, according to Fiscal.ai * Q4 net sales is expected to decline between 1% and 3% from a year earlier. Shares of Boston Scientific (BSX) tumbled 8% on Wednesday and hit their lowest level since October 2022 earlier in the session after the medical device maker lowered its annual sales outlook and said it expects fourth-quarter revenue to decline. BSX shares are on track for their fifth loss in six sessions. Boston Scientific cuts Q4 sales forecast. Boston Scientific said it expects fourth quarter (Q4) net sales to decline between 1% and 3% from a year earlier. For full year 2026, the company expects reported sales growth of about 4.25%, down from its previous forecast of 5.5% to 6.5%. Organic sales growth is projected at 3.75%, down from an earlier estimate of 5% to 6%. The company also lowered its full-year adjusted earnings outlook to $3.16 to $3.18 per share, down from $3.28 to $3.32 per share. Cybersecurity attack to disrupt FY 2026 financial performance. In August, Boston Scientific disclosed a cybersecurity incident that disrupted manufacturing, order processing, and shipments globally. The company subsequently warned that the disruptions would materially affect its 2026 financial performance, although it expected to recover some lost revenue as operations gradually resumed. On Wednesday, CEO Mike Mahoney acknowledged the difficult year but said he remained "confident in our long-term strategy," citing the company's product portfolio and pipeline of new technologies. Meanwhile, Q3 net sales rose 1.5% to $5.14 billion, exceeding Wall Street estimates of $5.04 billion, according to Fiscal.ai. Adjusted earnings per share slipped to $0.73 from $0.75 last year, but narrowly beat consensus estimates of $0.72 per share. Retail turns bullish on BSX. Despite the slump, retail sentiment surrounding BSX on Stocktwits flipped to 'bullish' from 'bearish' over the past 24 hours, amid 'high' message volumes. The stock has been under strong selling pressure so far this year, crashing more than 56%. Also read: WEN Stock Surges 15% As Trian Fund Offers $1.4B To Take The Burger Chain Private For updates and corrections, email newsroom[at]stocktwits[dot]com.< Stay updated with all the latest Business News, including market trends, Share Market News, stock updates, taxation, IPOs, banking, finance, real estate, savings, and investments. Track daily Gold Price changes, updates on DA Hike, and the latest developments on the 8th Pay Commission. Get in-depth analysis, expert opinions, and real-time updates to make informed financial decisions. Download the Asianet News Official App from the Android Play Store and iPhone App Store to stay ahead in business. 0 Comments / 0 New

Stock market today, Oct. 28: Boston Scientific slips 6% after cutting Q4 sales and full-year EPS guidance on cyberattack impact. Today, Oct. 28, 2026, the medical device maker slashed profit expectations after an August cyberattack continued disrupting operations. BSX - Boston Scientific. $42.43 -$2.63 (-5.84%) NYSE · As of 4:00 PM ET 10/28/26 BSX · 1M -3.81% Key data points. Market cap $65.30B Day's range $39.57 - $43.92 52wk range $39.57 - $105.65 Volume 69.8M Avg volume 19.3M Gross margin 66.36% Boston Scientific (BSX -5.84%), a global medical device maker focused on interventional cardiology and specialty devices, closed at $42.44, down 5.81%. Investors are focused on the cyberattack's lingering disruption and the company's lower fourth-quarter and full-year guidance. Trading volume reached 66.8M shares, coming in about 234% above its three-month average of 20.0M shares. How the markets moved today. S&P 500 (^GSPC +0.28%) closed at 7,744, up 0.28%, while the Nasdaq Composite (^IXIC +0.27%) finished at 26,550, up 0.27%. In the medical devices sector, Medtronic (MDT +0.88%) closed at $94.82, up 0.93%, and Abbott Laboratories (ABT -0.45%) closed at $102.67, down 0.42%, after fresh outlook pressure kept the group in focus. What this means for investors. Boston Scientific guided for 3% to 5% sales growth and $0.80 to $0.82 in adjusted EPS for Q3, and came up shy of both figures today, delivering a 1.5% sales increase and $0.73 in adjusted EPS. Management blamed an eight-day disruption from a cyberattack as the primary culprit, estimating it cost the company 300 basis points in sales growth and $0.07 in adjusted EPS. Making matters worse, the company doesn't believe an immediate turnaround is in sight, guiding for 3.75% sales growth in 2026; rather, a slow rebuilding is more likely over the next year or two. CEO Mahoney explained, "We believe that 2027 will be the trough in the cycle and we have several investments and new innovations coming over the course of the next 3 years." That said, BSX shares now trade at just 13 times forward earnings, so it wouldn't take massive growth to potentially spark such a turnaround - especially considering the company may have upside incoming from its pending acquisition of Penumbra, if it can integrate the deal successfully. I'm keeping an eye on Boston Scientific from a distance, but I'd only want to invest once I start to see signs of progress. Is Boston Scientific a smart long-term play? Before you buy stock in Boston Scientific, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now... and Boston Scientific wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of its recommendation, you'd have $337,166!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of its recommendation, you'd have $1,339,143!* Now, it's worth noting Stock Advisor's total average return is 904% - a market-crushing outperformance compared to 213% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors. *Stock Advisor returns as of October 28, 2026.